|
 |
| home > pmps > winter 2001 > medical and pharmaceutical translation - the need for a specialist |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
The globalisation of business has led to the need for the medical and pharmaceutical industries to simultaneously satisfy the requirements of regulatory authorities, including submission of information in a variety of languages. For example, those pharmaceutical companies submitting a marketing authorisation application in order to fulfil EU dossier requirements must provide a summary of product characteristics (Part IB), labelling information and a patient information leaflet in every official EU language. In addition, there are often layout requirements and the need to use phrase constructions that are fixed and mandatory. Finally, similar requirements also apply to CE Marking related documentation for the medical devices market. Only a professional and specialised company can provide the expertise needed for this sort of demanding translation work.
To work as a translator, a person must not only be fluent in multiple languages, but also have the academic foundation upon which to base a thorough understanding of the current status and terminology of highly specialised areas of business, law, technology, economy and health care. The translator must have a solid linguistic education.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
7th Annual Pharma Packaging and Labelling conference
17 September - 18 October 2008, Barcelona
7th Annual Pharma Packaging and Labelling conference will bring
together experts from leading pharma manufacturers to present case study driven
presentations on critical industry-wide issues.
Attending this event will give you an opportunity to discuss with fellow
packaging and labelling professionals and share your views on these important
matters.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
